Navigation Links
IDM Pharma Reports 2008 Financial Results
Date:3/31/2009

ith the approval of MEPACT in Europe, many young patients and their families have a new treatment option for this devastating disease for the first time in nearly 20 years. We wish to thank the many patients, their families, patient advocates, clinicians and the European regulators who were instrumental in the approval of MEPACT. As we complete our evaluation of the strategic options available to the Company, we continue to believe that the survival benefit of MEPACT warrants U.S. regulatory approval as well and that it should ultimately be made available to patients."

Details of Financial Results

Total revenues in the quarter ended December 31, 2008 were $0.3 million compared to total revenues of $5.6 million for the quarter ended December 31, 2007. Total revenues were $3.1 million for the year ended December 31, 2008, compared to total revenues of $14.6 million for the year ended December 31, 2007. Revenues in both the year ended December 31, 2008 and 2007 were primarily in connection with the Company's collaboration agreement with sanofi-aventis. As a result of sanofi-aventis' decision to terminate its participation in the UVIDEM development program in December 2007, we will not receive further payments or revenues from sanofi-aventis related to UVIDEM.

Research and development (R&D) expenses in the quarter ended December 31, 2008 decreased to $1.0 million from $5.2 million in the prior year period. For the year ended December 31, 2008, R&D expenses decreased to $11.2 million from $22.3 million in 2007. The decreased R&D spending during the periods was related to a reduction in spending on MEPACT (mifamurtide) and UVIDEM development, as well as reductions associated with lower headcount and closing of our Paris, France office.

Selling and marketing and general and administrative (SG&A) expenses were $3.0 million for the quarter ended December 31, 2008 compared with $2.9 mill
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
2. The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
3. Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio
4. VIA Pharmaceuticals Complies With NASDAQ Rules
5. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
9. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
10. Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
11. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , July 3, 2015  Pomerantz LLP announces that ... Biotechnology, Inc. ("Puma" or the "Company")(NYSE: PBYI ) ... in United States District Court, Central District of ... on behalf of a class consisting of all persons ... 2014 and May 13, 2015 inclusive (the "Class Period").  ...
(Date:7/2/2015)... Ill. , July 2, 2015 College ... Colton Eakins are gaining invaluable real-world experiences while ... Technology this summer. The students will be ... Jeff Wereszczynski,s research group at IIT. The internship ... Tom Carter , Physics; Dr. Kathy Finan ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... Sleepless nights ... an individual’s quality of sleep, launched its Indiegogo campaign on June 23. Sound sleepers ... voice command technology makes it effortless to use, while the integration of the Bluetooth ...
(Date:7/1/2015)... and PARIS , ... AgBiome, and Genective, key developer of biotech crops, ... discovery of new generations of insect control traits. ... control to counter the realities of advancing insect ... aligning AgBiome,s unique insect control technology with Genective,s ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4COD Students Participate in Prestigious Summer Internships 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3AgBiome and Genective collaborate to create novel insect-resistant crops 2
... CAMBRIDGE, England , May 25, 2010 ... ) announced today,an extension of the agreement under which O2h provides multi-FTE ... , , ... , Head of Chemistry said, "We are happy to have signed,this new ...
... , PARIS , May 25, 2010 ... - NEVO(TM), Incorporating RES ... Presented at EuroPCR 2010 , , , ... At 12 months the NEVO(TM) Sirolimus-eluting Coronary Stent has continued,to demonstrate excellent safety and ...
... NEW YORK , May 25, 2010 ... microprocessor technologies for use in,portable monitoring devices, announced that ... daily activity level of an individual and specifically,for use ... obese. The bracelet,designed both for children and adults, has ...
Cached Biology Technology:Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 3NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data 2NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data 3NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data 4NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data 5SPO Medical Announces Innovative Wellness Bracelet 2SPO Medical Announces Innovative Wellness Bracelet 3SPO Medical Announces Innovative Wellness Bracelet 4SPO Medical Announces Innovative Wellness Bracelet 5
(Date:6/15/2015)... , June 15, 2015 A ... from Telstra reveals the majority of US consumers using mobile ... via biometrics, such as fingerprint and voiceprint, instead of having ... According to Telstra,s " Mobile Identity   -   ... report, with smartphones now the primary channel used by ...
(Date:6/11/2015)... 2015 Daon, a global leader in ... IdentityX Mobile Authentication Platform v4.0 has been FIDO ... an industry consortium launched in 2013 to revolutionize ... authentication.  In order to receive certification, a company,s ... of tests that measure compliance and ensure interoperability ...
(Date:6/9/2015)... Research and Markets  ( http://www.researchandmarkets.com/research/xsgs2s/gesture ) ... Recognition & Touchless Sensing Market by Technology (Touch-based ... Product (Biometric & Sanitary Equipment) & by Geography ... their offering. The total gesture recognition ... $ 23.55 Billion by 2020 at a high ...
Breaking Biology News(10 mins):One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... Signals can tell cells to act cancerous, surviving, growing ... tell cells with cancerous characteristics to stop growing or ... TGF-beta does both sometimes promoting tumors and sometimes ... study recently published in the journal Oncogene ...
... Alexandria, VA -- Today, the Association for Molecular ... (USPTO) to place a moratorium on the issuing of ... Agency hearing on genetic diagnostic testing. AMP is the ... Liberties Union (ACLU) sponsored lawsuit challenging the validity of ...
... URBANA In a worst-case scenario simulation ... that establishing a good surveillance system and raising a ... to the Mexican cattle industry should an outbreak of ... "For diseases that spread very quickly, such as foot-and-mouth, ...
Cached Biology News:Study details on-off switch that promotes or suppresses breast cancer 2AMP testifies at USPTO 2Study simulates effects of foot-and-mouth disease outbreak in Mexico 2Study simulates effects of foot-and-mouth disease outbreak in Mexico 3
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
...
...
Biology Products: